YMTX - Yumanity Therapeutics Non-GAAP EPS of -$0.45 revenue of $1.66M
- Yumanity Therapeutics press release ( NASDAQ: YMTX ): Q2 Non-GAAP EPS of -$0.45.
- Revenue of $1.66M (-21.3% Y/Y).
- As of June 30, 2022, cash, cash equivalents and investments were $11.8 million, compared to $36.5 million as of December 31, 2021.
For further details see:
Yumanity Therapeutics Non-GAAP EPS of -$0.45, revenue of $1.66M